Peptilogics uses a computational platform to revolutionize drug discovery by designing a new class of antibiotics with a novel mechanism of action derived from their eCAP. Their lead clinical stage peptide therapeutic, PLG0206, is a broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for the treatment of prosthetic joint infections.